EFFICACY OF SENSITIVE TUBERCULOSIS TREATMENT WITH MALABSORPTION SYNDROM DURING IV ADMINISTRATION OF ANTI-TUBERCULOSIS DRUGS

Assesment of treatment efficacy in patients with sensitive lung tuberculosis (TB) with malabsorption syndrome during IV administration of anti-tuberculosis drugs (ATD). A lactulose-mannitol test was performed to establish the presense of malabsorption syndrome (MS). The study included 54 patients with sensitive first diagnosed lung tuberculosis (SFDT) and a low indicator of intestine penetration (1-3). Treatment in the main group (1) and in the control group (2) in the intensive chemotherapy phase (ICTP) was performed according to a standard scheme. Optimization of the treatment was performed in group 1 by IV administration of isoniazid (marketing name “Bitub”), rifampicin (marketing name “Rifonat”), etambutol (marketing name “inbutol”); manufacturer “Yuriya-Farm” and oral administration of pyrazinamid. Patients in the control group were treated with tablet forms of ATD. Study analysis has shown a decrease in absorption abilities of the small intestine in 58,9% of the first diagnosed TB cases, a different degree of impairment of absorption is met with the same frequency in both study groups and a disruption of both para- and transcellular transport is observed. During the dynamics of the optimized treatment by the end of ICTP bacteria secretion was ceased by 100% in group 1, and by у 53,9 % (р In patients with SFDT and presence of moderate or severe disruption of intestinal penetration, the proposed schemes of optimized therapy in the intensive treatment phase with IV administration of standard drugs are increasing the quantity of bacteria secretion cessation up to 2,1 times.